The Oncogenic Lung Cancer Fusion Kinase CD74-ROS Activates a Novel Invasiveness Pathway through E-Syt1 Phosphorylation
Patients with lung cancer often present with metastatic disease and therefore have a very poor prognosis. The recent discovery of several novel ROS receptor tyrosine kinase molecular alterations in non–small cell lung cancer (NSCLC) presents a therapeutic opportunity for the development of new targe...
Main Authors: | Johnson, Hannah, White, Forest M., Jun, Hyun Jung, Bronson, Roderick T., de Feraudy, Sebastien, Charest, Alain |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biological Engineering |
Format: | Article |
Language: | en_US |
Published: |
American Association for Cancer Research
2014
|
Online Access: | http://hdl.handle.net/1721.1/89034 https://orcid.org/0000-0002-1545-1651 |
Similar Items
-
Analysis of CD74 Occurrence in Oncogenic Fusion Proteins
by: Jasmine Vargas, et al.
Published: (2023-11-01) -
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1.
by: Alessi, DR, et al.
Published: (1994) -
Structural Aspects of the ROS1 Kinase Domain and Oncogenic Mutations
by: Juliana F. Vilachã, et al.
Published: (2024-01-01) -
Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression
by: Tara L. Peters, et al.
Published: (2023-11-01) -
Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
by: Sudarshan R Iyer, et al.
Published: (2023-10-01)